\
&
Contact us
\
&
Contact us
Published on | 1 month ago
Programmes HealthThe Korea-EU Research Centre (KERC) is organising a Korea-EU Horizon Europe Researchers Networking Forum on advanced biotechnology in Brussels between 1 and 3 July 2025,. The forum aims to foster collaboration between Korean and European researchers in advanced biotechnology, within the framework of Horizon Europe work programme 2025 - Cluster 1 (Health). Research list of relevant topisc: https://k-erc.eu/wp-content/uploads/2025/05/Horizon-Europe-2025-Advanced-Biotechnology-Calls.pdf
The event will bring together 12 researchers from Korea and 24 researchers from European countries (including associate countries), to exchange knowledge, explore joint research opportunities, and build lasting international networks. Each selected researcher will be given a 15-minute presentation slot to introduce their research and interests.
The Call for Applications for European researchers to present their research at the event is currently open. Deadline to Apply: 31 May 2025, 24:00 (CET).
More information and the link to apply on the event's webpage.
Alongside the selected researchers (session speakers), additional attendees may include other researchers, NCPs, consultants, support officers, and stakeholders. Registration for additional attendees opens in June. Places will be limited.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
